LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Accueil・Liste d'Actions・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Fermé

3.33 -7.5

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.3

Max

3.62

Chiffres clés
By Trading Economics
Revenu	-511K -28M
Ventes	-13M 2.6M
BPA	-0.47
Marge bénéficiaire	-1,077.401
Employés	141
EBITDA	-455K -29M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+318.23% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-5.4M 229M
Ouverture précédente	10.83
Clôture précédente	3.33

Voyager Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 juin 2026, 21:51 UTC

Principaux Mouvements du Marché

Merlin Shares Rally After Defense Department's Design Review Wraps

4 juin 2026, 23:46 UTC

Market Talk

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 juin 2026, 23:44 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 juin 2026, 23:42 UTC

Acquisitions, Fusions, Rachats

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 juin 2026, 23:41 UTC

Acquisitions, Fusions, Rachats

Energy Resources of Australia to Enter Trading Halt

4 juin 2026, 23:34 UTC

Market Talk

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 juin 2026, 23:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 juin 2026, 23:31 UTC

Market Talk

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 juin 2026, 23:31 UTC

Market Talk

Global Equities Roundup: Market Talk

4 juin 2026, 23:08 UTC

Market Talk

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 juin 2026, 22:41 UTC

Market Talk

Australia Shares Set to Rise at the Open -- Market Talk

4 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4 juin 2026, 20:44 UTC

Acquisitions, Fusions, Rachats

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 juin 2026, 20:16 UTC

Market Talk

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 juin 2026, 20:15 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 juin 2026, 19:46 UTC

Market Talk

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 juin 2026, 19:38 UTC

Market Talk

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 juin 2026, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 juin 2026, 18:47 UTC

Acquisitions, Fusions, Rachats

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 juin 2026, 18:38 UTC

Résultats

Money Quote: Tech Weakness in Context -- WSJ

4 juin 2026, 18:24 UTC

Résultats

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 juin 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 juin 2026, 16:58 UTC

Résultats

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 juin 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 juin 2026, 16:38 UTC

Résultats

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 juin 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

4 juin 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

4 juin 2026, 16:13 UTC

Market Talk

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 juin 2026, 16:11 UTC

Market Talk

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 juin 2026, 15:56 UTC

Market Talk

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Comparaison

Variation de prix

Voyager Therapeutics Inc prévision

Objectif de Prix

By TipRanks

318.23% hausse

Prévisions sur 12 Mois

Moyen 15.14 USD 318.23%

Haut 25 USD

Bas 8 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

9 ratings

Achat

Maintien

Vente

Basé sur 9 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.